{"nctId":"NCT02074345","briefTitle":"Phase III Study of Intramuscular TAK-816 in Healthy Infants","startDateStruct":{"date":"2014-03"},"conditions":["Healthy Volunteers","Haemophilus Influenzae Type b, Prevention"],"count":31,"armGroups":[{"label":"TAK-816 0.5 mL","type":"EXPERIMENTAL","interventionNames":["Biological: TAK-816"]}],"interventions":[{"name":"TAK-816","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy Japanese infants.\n2. Male or female infants aged 2-6 months (≥2 and \\<7 months) at the time of the first dose of investigational product (excluding hospitalized infants).\n3. Infants whose parents or legal guardians have agreed to cooperate with the investigator during the study period.\n4. The legal guardian signed and dated a written, informed consent form prior to the initiation of any study procedures.\n\nExclusion Criteria:\n\n1. Any serious acute illness.\n2. Any underlying cardiovascular, renal, hepatic, or hematologic disease, and/or developmental disorder.\n3. History of possible Haemophilus influenzae type b (Hib) infection.\n4. Previously diagnosed immunodeficiency.\n5. Documented history of anaphylaxis to any ingredients of the investigational product (e.g., diphtheria toxoid).\n6. A history of convulsions.\n7. Previous administration of another Hib vaccine.\n8. Treatment with any live vaccine during the 27 days before the first dose of TAK-816 or with any inactivated vaccine during the 6 days before dosing.\n9. Prior participation in any clinical study or post-marketing clinical study.\n10. Previously receipt of blood transfusions, gamma globulin preparations (except monoclonal antibody products not containing any components of Hib as antigens), systemic immunosuppressive therapy, or systemic corticosteroids, or a plan to receive any of these products during the study period.\n11. Presence of thrombocytopenia or coagulopathy.\n12. Children considered ineligible for the study for other reasons by the investigator or subinvestigator.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"6 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product. Among these, events which are considered possibly associated with a medicinal product are defined as adverse reactions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Reactions Related to Body Temperature (Pyrexia)","description":"Body temperature was assessed for 14 days after each vaccination and was recorded by the caregiver in a diary. Adverse reactions related body temperature was reported as pyrexia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Reactions Related to Local Reactions","description":"Local Reactions were assessed 14 days after each vaccination and were recorded by the caregiver in a diary. Local reactions (injection site) were erythema, swelling, induration and pain (tenderness).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Reactions Related to Systemic Reactions","description":"Systemic Reactions were assessed 14 days after each vaccination and were recorded by the caregiver in a diary. Systemic reactions were rash, irritability, crying, decreased appetite, vomiting, diarrhoea, somnolence (sleepiness) and insomnia (sleeplessness).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participant With Anti-PRP Antibody Titer ≥ 1.0 μg/mL","description":"Blood was collected and was sent to a central laboratory for the evaluation of anti-PRP antibody titer against Haemophilus influenzae type b (Hib) as an assessment of immunogenicity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participant With Anti-PRP Antibody Titer ≥ 0.15 μg/mL","description":"Blood was collected and was sent to a central laboratory for the evaluation of anti-PRP antibody titer against Hib as an assessment of immunogenicity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Anti-PRP Antibody","description":"Blood was collected and was sent to a central laboratory for the evaluation of anti-PRP antibody titer against Hib as an assessment of immunogenicity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.354","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.682","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.087","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.334","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":31},"commonTop":["Nasopharyngitis","Pyrexia","Diarrhoea","Eczema","Injection site erythema"]}}}